about
Modeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cellsPhase 0 clinical chemoprevention trial of the Akt inhibitor SR13668Phase 0 trials: expediting the development of chemoprevention agents.Phase zero trials: a novel approach in drug development process.Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer.State of the Science: Cancer Complementary and Alternative Medicine Therapeutics Research-NCI Strategic Workshop Highlights of Discussion Report.
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The statistics of phase 0 trials.
@en
The statistics of phase 0 trials.
@nl
type
label
The statistics of phase 0 trials.
@en
The statistics of phase 0 trials.
@nl
prefLabel
The statistics of phase 0 trials.
@en
The statistics of phase 0 trials.
@nl
P2093
P2860
P356
P1476
The statistics of phase 0 trials.
@en
P2093
Anthony J Murgo
James H Doroshow
Joseph E Tomaszewski
Larry V Rubinstein
Ralph E Parchment
Robert Kinders
Seth M Steinberg
Shivaani Kummar
P2860
P304
P356
10.1002/SIM.3840
P407
P577
2010-05-01T00:00:00Z